An integrated oncology platform from Crown Bioscience, a global drug discovery and development services company, has helped to advance the preclinical development of a HERA-GITRL immunotherapy from Apogenix for non-small cell lung cancer (NSCLC) and head and neck cancer.
Head and neck
Data demonstrating the potential clinical use and the benefits of using the Crown Bioscience platform in preclinical efficacy testing have been presented by Apogenix at the AACR annual meeting.
“CrownBio's integrated oncology platform confirmed our agent's efficacy in NSCLC and head and neck cancers,” said Dr Mauricio Redondo Müller, director, Preclinical Development at Apogenix. “The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage.”
“It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development, Crown Bioscience. “Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area.”